Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

M Noshela Ghazanfar; S F Thomsen

doi:10.23822/eurannaci.1764-1489.08

Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

M Noshela Ghazanfar, S F Thomsen

4 Citations (Scopus)

Abstract

Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

Original language	English
Journal	European Annals of Allergy and Clinical Immunology
Volume	49
Issue number	6
Pages (from-to)	284-285
Number of pages	2
ISSN	1764-1489
DOIs	https://doi.org/10.23822/eurannaci.1764-1489.08
Publication status	Published - Nov 2017

Access to Document

10.23822/eurannaci.1764-1489.08

volume-transient-hair-loss-patients-with-1467allasp1.pdfFinal published version, 68.8 KB

Cite this

@article{1f7110adf40942dabd72ff37eddb52a3,

title = "Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab",

abstract = "Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.",

author = "{Noshela Ghazanfar}, M and Thomsen, {S F}",

year = "2017",

month = nov,

doi = "10.23822/eurannaci.1764-1489.08",

language = "English",

volume = "49",

pages = "284--285",

journal = "European Annals of Allergy and Clinical Immunology",

issn = "1764-1489",

publisher = "Meditions Carline",

number = "6",

}

TY - JOUR

T1 - Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

AU - Noshela Ghazanfar, M

AU - Thomsen, S F

PY - 2017/11

Y1 - 2017/11

N2 - Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

AB - Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

U2 - 10.23822/eurannaci.1764-1489.08

DO - 10.23822/eurannaci.1764-1489.08

M3 - Journal article

C2 - 29249138

SN - 1764-1489

VL - 49

SP - 284

EP - 285

JO - European Annals of Allergy and Clinical Immunology

JF - European Annals of Allergy and Clinical Immunology

IS - 6

ER -

Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

Abstract

Access to Document

Fingerprint

Cite this